XENE — Xenon Pharmaceuticals Inc. Stock Price, Chart & AI Report

Neutral Feb 23, 2026 • 15:18 UTC The Motley Fool • Jonathan Ponciano

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

SYRE RLAY ALKS XENE biotech monoclonal antibodies inflammatory bowel disease preclinical stage

Sentiment note

Mentioned as a comparable holding in Commodore Capital's portfolio (5.4% of AUM, $80.68M) but no specific news or analysis provided in the article.

Positive Dec 4, 2025 • 22:20 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals granted 39,250 share options to five new non-officer employees, with options vesting over four years and an exercise price of $44.61 per share.

XENE equity grants share options neuroscience pharmaceutical employee incentives

Sentiment note

Company is expanding workforce and providing competitive equity compensation, indicating growth and confidence in future prospects

Positive Aug 1, 2025 • 20:55 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.

XENE equity grants share options neuroscience biopharmaceutical

Sentiment note

Company is expanding workforce and offering competitive equity compensation, indicating growth and financial stability

Positive May 2, 2025 • 20:42 UTC GlobeNewswire Inc. • N/A

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Inc. announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units. The share options have an exercise price of $38.28 per common share and vest over four years, while the performance share units will vest based on the achievement of certain predefined milestone-based objectives over an approximately three-year period.

XENE Xenon Pharmaceuticals equity inducement grants share options performance share units

Sentiment note

The article announces that Xenon Pharmaceuticals is granting equity inducement grants to new employees, which is a positive sign of the company's growth and commitment to attracting and retaining talent.

Positive Feb 20, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight

The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.

XENE OVID epilepsy market assessment partial epilepsy chronic focal epilepsy drug-resistant epilepsy emerging therapies

Sentiment note

The article mentions Xenon Pharmaceutical's XEN1101 as one of the emerging therapies expected to launch during the forecast period, indicating a positive outlook for the company.

Unknown Jul 2, 2024 • 13:22 UTC Zacks Investment Research • Zacks Equity Research

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

CGEN XENE ALXO LBPH

Unknown May 28, 2024 • 12:30 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

XENE Calendar of Events Clinical Study

Unknown May 10, 2024 • 12:17 UTC Zacks Investment Research • Zacks Equity Research

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

NBIX ANIP XENE ANVS

Unknown May 9, 2024 • 20:01 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025

XENE Earnings Releases and Operating Results

Unknown May 8, 2024 • 20:01 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

XENE Calendar of Events Conference Calls/ Webcasts

Unknown May 7, 2024 • 20:01 UTC GlobeNewswire Inc. • Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY.

XENE Conference Calls/ Webcasts

Unknown May 6, 2024 • 16:00 UTC Zacks Investment Research • Zacks Equity Research

What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock

Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

XENE